SEARCH

SEARCH BY CITATION

References

  • 1
    Kato M, Kephart GM, Talley NJ, Wagner JM, Sarr MG, Bonno M et al. Eosinophil infiltration and degranulation in normal human tissue. Anat Rec 1998;252: 418425.
  • 2
    Straumann A, Simon HU. The physiological and pathophysiological roles of eosinophils in the gastrointestinal tract. Allergy 2004;59: 1525.
  • 3
    Mihm MC, Soter NA, Dvorak HF, Austen KF. The structure of normal skin and the morphology of atopic eczema. J Invest Dermatol 1976;67: 305312.
  • 4
    Steigleder GK, Inderwisch R. Eosinophilic leucocytes in the skin lesions of psoriais and atopic dermatitis. Arch Dermatol Res 1975;254: 253255.
  • 5
    Braun-Falco O, Burg G. Celluläres infiltrat und Capillaren bei Neurodermitis diffusa. Arch Derm Forsch 1974;249: 113124.
  • 6
    Kiehl P, Falkenberg K, Vogelbruch M, Kapp A. Tissue eosinophilia in acute and chronic dermatitis: a morphometric approach using quantitative image analysis of immunostaining. Br J Dermatol 2001;145: 720729.
  • 7
    Spergel JM, Mizoguchi E, Oettgen H, Bhan AK, Geha RS. Roles of Th1 and Th2 cytokines in a murine model of allergic dermatitis. J Clin Invest 1999;103: 11031111.
  • 8
    Kagi MK, Joller-Jemelka H, Wüthrich B. Correlation of eosinophils, eosinophilic cationic protein and soluble interleukin-2 receptor with the clinical activity of atopic dermatitis. Dermatology 1992;185: 8892.
  • 9
    Uehara M, Izukura R, Sawai T. Blood eosinophilia in atopic dermatitis. Clin Exp Dermatol 1990;15: 264266.
  • 10
    Akdis CA, Akdis M, Simon D, Dibbert B, Weber M, Gratzl S et al. T cells and T cell-derived cytokines as pathogenic factors in the nonallergic form of atopic dermatitis. J Invest Dermatol 1999;113: 628634.
  • 11
    Sur S, Glitz DG, Kita H, Kujawa SM, Peterson EA, Weiler DA et al. Localization of eosinophil-derived neurotoxin and eosinophil cationic protein in neutrophilic leukocytes. J Leukoc Biol 1998;63: 715722.
  • 12
    Czech W, Krutmann J, Schopf E, Kapp A. Serum eosinophil cationic protein (ECP) is a sensitive measure for disease activity in atopic dermatitis. Br J Dermatol 1992;126: 351355.
  • 13
    Halmerbauer G, Frischer T, Koller DY. Monitoring of disease activity by measurement of inflammatory markers in atopic dermatitis in childhood. Allergy 1997;52: 765769.
  • 14
    Taniuchi S, Chihara J, Kojima T, Yamamoto A, Sasai M, Kobayashi Y. Serum eosinophil derived neurotoxin may reflect more strongly disease activity in childhood atopic dermatitis than eosinophil cationic protein. J Dermatol Sci 2001;26: 7982.
  • 15
    Caproni M, Agata AD, Cappelli G, Fabbri P. Modulation of serum eosinophilic cationic protein levels by cyclosporin in severe atopic dermatitis. Br J Dermatol 1996;135: 336.
  • 16
    Stevens SR, Hanifin JM, Hamilton T, Tofte SJ, Cooper KD. Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels. Arch Dermatol 1998;134: 799804.
  • 17
    Walker C, Kagi MK, Ingold P, Braun P, Blaser K, Bruijnzeel-Koomen CA et al. Atopic dermatitis: correlation of peripheral blood T cell activation, eosinophilia and serum factors with clinical severity. Clin Exp Allergy 1993;23: 145153.
  • 18
    Krutmann J, Czech W, Diepgen T, Niedner R, Kapp A, Schopf E. High-dose UV A1 therapy in the treatment of patients with atopic dermatitis. J Am Acad Dermatol 1992;26: 225230.
  • 19
    Kim TY, Park HJ, Kim CW. Eosinophil cationic protein (ECP) level and its correlation with eosinophil number or IgE level of peripheral blood in patients with various skin diseases. J Dermatol Sci 1997;15: 8994.
  • 20
    Wassom DL, Loegering DA, Solley GO, Moore SB, Schooley RT, Fauci AS et al. Elevated serum levels of the eosinophil granule major basic protein in patients with eosinophilia. J Clin Invest 1981;67: 651661.
  • 21
    Tischendorf FW, Brattig NW, Lintzel M, Buttner DW, Burchard GD, Bork K et al. Eosinophil granule proteins in serum and urine of patients with helminth infections and atopic dermatitis. Trop Med Int Health 2000;5: 898905.
  • 22
    Breuer K, Kapp A, Werfel T. Urine eosinophil protein X (EPX) is an in vitro parameter of inflammation in atopic dermatitis in the adult age. Allergy 2001;56: 780784.
  • 23
    Oymar K, Bjerknes R. Urinary eosinophil protein X in children with atopic dermatitis: relation to atopy and disease activity. Allergy 2000;55: 964968.
  • 24
    Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2003;111: S486S494.
  • 25
    Leiferman KM, Ackerman SJ, Sampson HA, Haugen HS, Venencie PY, Gleich GJ. Dermal deposition of eosinophil-granule major basic protein in atopic dermatitis: comparison with onchocerciasis. N Engl J Med 1985;313: 282285.
  • 26
    Leiferman KM, Fujisawa T, Gray BH, Gleich GJ. Extracellular deposition of eosinophil and neutrophil granule proteins in the IgE-mediated cutaneous lete phase reaction. Lab Invest 1990;62: 579589.
  • 27
    Cheng JF, Ott NL, Peterson EA, George TJ, Hunkee MJ, Gleich GJ et al. Dermal eosinophils in atopic dermatitis undergo cytolytic degeneration. J Allergy Clin Immunol 1997;99: 683692.
  • 28
    Leiferman KM. A role for eosinophils in atopic dermatitis. J Am Acad Dermatol 2001;45: S21S24.
  • 29
    Denburg JA, Telizyn S, Messner H, Lim B, Jamal N, Ackerman SJ et al. Heterogeneity of human peripheral blood eosinophil-type colonies: evidence for a common basophil-eosinophil progenitor. Blood 1985;66: 312318.
  • 30
    Linden M, Svenson C, Andersson M, Greiff L, Andersson E, Denburg JA et al. Circulating eosinophil/basophil progenitors and nasal mucosal cytokines in seasonal allergic rhinitis. Allergy 1999;54: 212219.
  • 31
    Cyr MM, Denburg JA. Systemic aspects of allergic diseases: the role of the bone marrow. Current Opinion in Immunology 2001;13: 727732.
  • 32
    Foster P, Hogan P, Ramsay AJ, Matthaei KI, Young IG. Interleukin-5 deficiency abolishes eosinophilia, airway hyperreactivity and lung damage in a mouse asthma model. J Exp Med 1996;83: 195201.
  • 33
    Dent LA, Strath M, Mellor AL, Sanderson CJ. Eosinophilia in transgenic mice expressing interleukin 5. J Exp Med 1990;172: 14251431.
  • 34
    Nashinakamura R, Miyajima A, Mee PJ, Tybulewicz VLJ, Murray R. Hematopooiesis in mice lacking the entire granulocyte-macrophage colony-stimulating factor/interleukin-3/interleukin-5 functions. Blood 1996;88: 24582464.
  • 35
    Saito H, Howie K, Wattie J, Denburg A, Ellis R, Inman MD et al. Allergen-induced murine upper airway inflammation: local and systemic changes in murine experimental allergic rhinitis. Immunology 2001;104: 226234.
  • 36
    Palframan RT, Collins PD, Severs NJ, Rothery S, Williams TJ, Rankin SM. Mechanisms of acute eosinophil mobilization from the bone marrow stimulated by interleukin-5: the role of specific adhesion molecules and phosphatidylinositol 3-kinase. J Exp Med 1998;188: 16211632.
  • 37
    Palframan RT, Collins PD, Williams TJ, Rankin SM. Eotaxin induces a rapid release of eosinophils and their progenitors from the bone marrow. Blood 1998;91: 22402248.
  • 38
    Broide D, Sriramarao P. Eosinophil trafficking to sites of allergic inflammation. Immunol Rev 2001;179: 163172.
  • 39
    Bochner BS, Charlesworth EN, Lichtenstein LM. Interleukin-1 is released at sites of human cutaneous allergic reactions. J Allergy Clin Immunol 1990;86: 830839.
  • 40
    Mullarkey M, Leiferman KM, Peters MS, Caro I, Roux ER, Hanna RK et al. Human cutaneous allergic late-phase response is inhibited by soluble IL-1 receptor. J Immunol 1994;52: 20332041.
  • 41
    Wakita H, Sakamoto T, Tokura Y, Takigawa M. E-selectin and vascular adhesion molecule 1 as critical adhesion molecules for infiltration of T lymphocytes and eosinophils in atopic dermatitis. J Cutan Pathol 1993;21: 3339.
  • 42
    Dobrina A, Menegazzi R, Carlos TM, Nardon E, Cramer R, Zacchi T et al. Mechanisms of eosinophil adherence to cultured vascular endothelial cells. J Clin Invest 1991;88: 2026.
  • 43
    Schleimer RP, Sterbinsky SA, Kaiser J, Bickel CA, Klunk DA, Tomioka K et al. IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium. Association with expression of VCAM-1. J Immunol 1992;148: 10861092.
  • 44
    Moser R, Fehr J, Bruijnzeel LB. IL-4 controls the selective endothelium-driven transmigration of eosinophils from allergic individuals. J Immunol 1992;149: 14321438.
  • 45
    Schnyder B, Lugli S, Feng N, Etter H, Lutz RA, Ryffel B et al. IL-4 and IL-13 bind to a shared heterodimeric complex on endothelial cells mediating vascular adhesion molecule-1 induction in the absence of the common γ chain. Blood 1996;87: 42864295.
  • 46
    Fernvik E, Hallden G, Lundahl J, Raud J, Alkner U, Van Hage-Hamsten M et al. Allergen-induced accumulation of eosinophils and lymphocytes in skin chambers is associated with increased levels of interleukin-4 and sVCAM-1. Allergy 1999;54: 455463.
  • 47
    Elsner J, Kapp A. Regulation and modulation of eosinophil effector functions. Allergy 1999;54: 1526.
  • 48
    DiScipio R, Daffern P, Jagels MA, Broide DH, Sriramarao P. C3a and C5a mediate the rapid activation dependent conversion of rolling eosinophils to firmly adherent eosinophils in vivo. J Immunol 1999;162: 11271136.
  • 49
    Tager AM, Dufour JH, Goodarzi K, Bercury SD, Von Adrian UH, Luster AD. BLTR mediates leukotriene (4)-induced chemotaxis and adhesion and plays a dominant role in eosinophil accumulation in a murine model of peritonitis. J Exp Med 2000;192: 439446.
  • 50
    Hirai H, Tanaka K, Yoshie O, Ogawa K, Kenmotsu K, Takamori Y et al. Prostaglandin D2 selectively induces chemotaxis in T-helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 2001;193: 255262.
  • 51
    Bandeira-Melo C, Bozza PT, Dias BL, Cordeiro RS, Jose PJ, Martins MA et al. Lipoxin (LX) A4 and aspirin-triggered 15-epi-LXA4 block allergen-induced eosinophil trafficking. J Immunol 2000;164: 22672271.
  • 52
    Mochizuki M, Bartels J, Mallet AI, Christophers E, Schröder JM. IL-4 induces eotaxin: a possible mechanism of selective eosinophil recruitment in helminth infection and atopy. J Immunol 1998;160: 6068.
  • 53
    Wang J, Homer RJ, Chen Q, Elias JA. Endogenous and exogenous IL-6 inhibit aeroallergen-induced Th2 inflammation. J Immunol 2000;165: 40514061.
  • 54
    Wang J, Homer RJ, Hong L, Cohn L, Lee CG, Jung S et al. IL-11 selectively inhibits aeroallergen-induced pulmonary eosinphilia and Th2 cytokine production. J Immunol 2000;165: 22222231.
  • 55
    Zhao LL, Linden A, Sjöstrand M, Cui ZH, Lötvall J, Jordana M. IL-12 regulates bone marrow eosinophilia and airway eotaxin levels induced by airway allergen exposure. Allergy 2000;55: 749756.
  • 56
    Rothenberg ME, MacLean JA, Pearlman E, Luster AD, Leder P. Targeted disruption of the chemokine eotaxin partially reduces antigen-induced tissue eosinophilia. J Exp Med 1997;185: 785790.
  • 57
    Ying S, Taborda-Barate L, Meng Q, Humbert M, Kay MB. The kinetics of allergen-induced transcription of messenger RNA for monocyte chemotactic protein-3 and RANTES in the skin of human atopic subjects: relationship to eosinophil, T cell, and macrophage recruitment. J Exp Med 1995;181: 21532159.
  • 58
    Gonzalo JA, Lloyd CM, Wen D, Albar JP, Wells TN, Proudfoot A et al. The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness. J Exp Med 1998;188: 157167.
  • 59
    Dombrovicz D, Capron M. Eosinophils, allergy and parasites. Current Opin Immunology 2001;13: 716720.
  • 60
    Sallusto F, Mackay CR, Lanzavechia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol 2000;18: 593620.
  • 61
    Ponath PD, Qin S, Post TW, Wang J, Wu L, Gerard NP et al. Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils. J Exp Med 1996;183: 23492354.
  • 62
    Homey B, Zlotnik A. Chemokines in allergy. Curr Opin Immunol 1999;11: 626634.
  • 63
    Nagase H, Yamaguchi M, Jibiki S, Yamada H, Ohta K, Kawasaki H et al. Eosinophil chemotaxis by chemokines: a study by a simple photometric assay. Allergy 1999;54: 944950.
  • 64
    Hossny E, Aboul-Magd M, Bakr S. Increased plasma eotaxin in atopic dermatitis and acute urticaria in infants and children. Allergy 2001;56: 9961002.
  • 65
    Yawalkar N, Uguccioni M, Schärer J, Braunwalder J, Karlen S, Dewald B et al. Enhanced expression of eotaxin and CCR-3 in atopic dermatitis. J Invest Dermatol 1999;113: 4348.
  • 66
    Weilie M, Bryce PJ, Humbles AA, Laouini D, Yalcindag A, Alenius H et al. CCR-3 is essential for skin eosinophilia and airway hyperresponsiveness in a murine model of allergic skin inflammation. J Clin Invest 2002;109: 621628.
  • 67
    Masumoto A, Hemler ME. Multiple activation states of VLA-4. Mechanistic differences between adhesion to CS-1/fibronectin and to vascular cell adhesion molecule-1. J Biol Chem 1993;268: 228234.
  • 68
    Gleich GJ. Mechanisms of eosinophil associated inflammation. J Allergy Clin Immunol 2000;105: 651663.
  • 69
    Menzies-Gow A, Ying S, Sabroe I, Stubbs VL, Soler D, Williams T et al. Eotaxin and eotaxin-2 induce recruitment of eosinophils, basophils, neutrophils, and macrophages as well as features of early- and late-phase allergic reactions following cutaneous injection in human atopic and nonatopic volunteers. J Immunol 2002;169: 27122718.
  • 70
    Bruynzeel-Koomen CAFM, Van Wichen DF, Spry CJF, Venge P, Bruynzeel PLB. Active participation of eosinophils in patch test reactions to inhalant allergens in patients with atopic dermatitis. Br J Dermatol 1988;118: 229238.
  • 71
    Mitchell EB, Chapman MD, Pope FM, Crow J, Jouhal SS, Platts-Mills TAE. Basophils in allergen-induced patch test sites in atopic dermatitis. Lancet 1982;i: 127130.
  • 72
    Wakugawa M, Nakagawa H, Yamada N, Tamaki K. Chronologic analysis of eosinophil granule protein deposition and cell adhesion molecule expression in mite allergen-induced dermatitis in atopic subjects. Int Arch Allergy Immunol 1996;111: S5S11.
  • 73
    Niggemann B, Beyer K, Wahn U. The role of eosinophils and eosinophil cationic protein in monitoring oral challenge tests in children with food sensitive atopic dermatitis. J Allergy Clin Immunol 1994;94: 963971.
  • 74
    Simon HU. Eosinophil apoptosis in allergic diseases – an emerging new issue. Clin Exp Allergy 1998;28: 13211324.
  • 75
    Simon HU, Yousefi S, Schranz C, Schapowal A, Bachert C, Blaser K. Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. J Immunol 1997;158: 39023908.
  • 76
    Simon HU, Blaser K. Inhibition of programmed eosinophil death: a key pathogenic event for eosinophilia? Immunol Today 1995;16: 5355.
  • 77
    Simon HU. Eosinophil apoptosis – pathophysiologic and therapeutic implications. Allergy 2000;55: 910915.
  • 78
    Shinagawa K, Trifilieff A, Anderson GP. Involvement of CCR3-reactive chemokines in eosinophil survival. Int Arch Allergy Immunol 2003;130: 150157.
  • 79
    Wedi B, Raap U, Lewrick H, Kapp A. Delayed eosinophil programmed cell death in vitro: a common feature in inhalant allergy and extrinsic and intrinsic dermatitis. J Allergy Clin Immunol 1997;100: 536543.
  • 80
    Dibbert B, Daigle I, Braun D, Schranz C, Weber M, Blaser K et al. Role for Bcl-xL in delayed eosinophil apoptosis mediated by granulocyte-macrophage colony-stimulating factor and interleukin-5. Blood 1998;92: 778783.
  • 81
    Ploetz SG, Dibbert B, Abeck D, Ring J, Simon HU. Bcl-2 expression by eosinophils in a patient with hypereosinophilia. J Allergy Clin Immunol 1998;102: 10371040.
  • 82
    Ogawa K, Hashida R, Miyagawa M, Kagaya S, Sugita Y, Matsumoto K et al. Analysis of gene expression in peripheral blood eosinophils from patients with atopic dermatitis and in vitro cytokine-stimulated blood eosinophils. Clin Exp Immunol 2003;131: 436445.
  • 83
    Wedi B, Raap U, Kapp A. Significant delay of apoptosis and Fas resistance in eosinophils of subjects with intrinsic and extrinsic type of atopic dermatitis. Int Arch Allergy Immunol 1999;118: 234235.
  • 84
    Hebestreit H, Dibbert B, Balatti I, Braun D, Schapowal A, Blaser K et al. Disruption of Fas receptor signaling by nitric oxide in eosinophils. J Exp Med 1998;187: 415425.
  • 85
    Takafuji S, Bischoff SC, De Weck AL, Dahinden CA. IL-3 and IL-5 prime normal eosinophils to produce leukotriene C4 in response to soluble agonists. J Immunol 1991;147: 38553861.
  • 86
    Rothenberg ME, Owen WF, Silberstein DS, Soberman RJ, Austen KF, Stevens RL. Eosinophils cocultured with endothelial cells have increased survival and functional properties. Science 1987;237: 645647.
  • 87
    Sehmi R, Wardlaw AJ, Cromwell O, Kurihara K, Waltmann P, Kay AB. Interleukin-5 selectively enhances the chemotactic response of eosinophils obtained from normal but not eosinophilic subjects. Blood 1992;79: 29522959.
  • 88
    Tomioka K, MacGlashan DW, Lichtenstein LM, Bochner BS, Schleimer RP. GM-CSF regulates human eosinophil responses to F-Met peptide and platelet activating factor. J Immunol 1993;151: 49894997.
  • 89
    Dahinden CA, Zingg J, Maly FE, De Weck AL. Leukotriene production in human neutrophils primed by recombinant human granulocyte/macrophage colony-stimulating factor and stimulated with the complement component C5a and fMLP as second signals. J Exp Med 1988;167: 12811295.
  • 90
    Simon HU, Ploetz S, Simon D, Seitzer U, Braathen LR, Menz G et al. Interleukin-2 primes eosinophil degranulation in hypereosinophilia and Wells’ syndrome. Eur J Immunol 2003;33: 834839.
  • 91
    Simon HU, Weber M, Becker E, Zilberman Y, Blaser K, Levi-Schaffer F. Eosinophils maintain their capacity to signal and release eosinophilic cationic protein upon repetitive stimulation with the same agonist. J Immunol 2000;165: 40694075.
  • 92
    Yousefi S, Hemmann S, Weber M, Hoelzer C, Hartung K, Blaser K et al. IL-8 is expressed by human peripheral blood eosinophils. J Immunol 1995;154: 54815490.
  • 93
    Schmid-Grendelmeier P, Altznauer F, Fischer B, Bizer C, Straumann A, Menz G et al. Eosinophils express functional IL-13 in eosinophilic inflammatory diseases. J Immunol 2002;169: 10211027.
  • 94
    Bochner BS. Systemic activation of basophils and eosinophils: markers and consequences. J Allergy Clin Immunol 2000;106: S292S302.
  • 95
    Gounni AS, Lamkhioued B, Ochiai K, Tanaka Y, Delaporte E, Capron A et al. High-affinity IgE receptor on eosinophils is involved in defence against parasites. Nature 1994;367: 183186.
  • 96
    Seminario MC, Saini SS, MacGlashan DW, Bochner BS. Intracellular expression and release of FcεRIa by human eosinophils. J Immunol 1999;162: 68936900.
  • 97
    Kita H, Kaneko M, Bartemes KR, Weiler DA, Schimming AW, Reed CE et al. Does IgE bind to and activate eosinophils from patients with allergy? J Immunol 1999;162: 69016911.
  • 98
    Bandeira-Melo C, Sugiyama K, Woods LJ, Weller PF. Eotaxin elicits rapid vesicular transport-mediated release of preformed IL-4 from human eosinophils. J Immunol 2001;166: 48134817.
  • 99
    Woerly G, Roger N, Loiseau S, Dombrowicz D, Capron A, Capron M. Expression of CD28 and CD86 by human eosinophils and role in the secretion of type 1 cytokines (Interleukin 2 and interferon-gamma): inhibition by immunoglobulin A complexes. J Exp Med 1999;190: 487495.
  • 100
    Bandeira-Melo C, Bozza PT, Weller PF. The cellular biology of eosinophil eicosanoid formation and function. J Allergy Clin Immunol 2002;109: 393400.
  • 101
    Schauer U, Trube M, Jager R, Gieler U, Rieger CH. Blood eosinophils, eosinophil-derived proteins, and leukotriene C4 generation in relation to bronchial hyperreactivity in children with atopic dermatitis. Allergy 1995;50: 126132.
  • 102
    Sanak M, Simon HU, Szczeklik A. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 1997;350: 15991600.
  • 103
    Mawhorter SD, Kazura JW, Boom WH. Human eosinophils as antigen-presenting cells: relative efficacy for superantigen- and antigen-induced CD4+ T-cell proliferation. Immunology 1994;81: 584591.
  • 104
    Mori A, Suko M, Nishizaki Y, Kaminuma O, Matsuzaki G, Ito K et al. Regulation of interleukin-5 production by peripheral blood mononuclear cells from atopic patients with FK506, cyclosporin A and glucocorticoid. Int Arch Allergy Immunol 1994;104: S32S35.
  • 105
    Mori A, Kaminuma O, Suko M, Inoue S, Ohmura T, Hoshino A et al. Two distinct pathways of interleukin-5 synthesis in allergen-specific human T-cell clones are suppressed by glucocorticoids. Blood 1997;89: 28912900.
  • 106
    Meagher LC, Cousin JM, Seckl JR, Haslett C. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immunol 1996;156: 44224428.
  • 107
    Oehling AG, Akdis CA, Schapowal A, Blaser K, Schmitz M, Simon HU. Suppression of the immune system by oral glucocorticoid therapy in bronchial asthma. Allergy 1997;52: 144154.
  • 108
    Barnes PJ. Molecular mechanisms of corticosteroids in allergic diseases. Allergy 2001;56: 928936.
  • 109
    Heaton T, Mallon D, Venaille T, Holt P. Staphylococcal enterotoxin induced IL-5 stimulation as a cofactor in the pathogenesis of atopic disease: the hygiene hypothesis in reverse? Allergy 2003;58: 252256.
  • 110
    Simon D, Conus S, Vassina E, Braathen LR, Simon HU. Immunopharmacological effects of topical tacrolimus in atopic dermatitis. J Eur Acad Derm Venerol 2003;17: S156.
  • 111
    Noh GW, Lee KY. Blood eosinophils and serum IgE as predictors for prognosis of interferon-gamma therapy in atopic dermatitis. Allergy 1998;53: 12021207.
  • 112
    Breuckmann F, Von Kobyletzki G, Avermaete A, Pieck C, Kreuter A, Brockmeyer NH et al. Mononuclear cells in atopic dermatitis in vivo: immunomodulation of the cutaneous infiltrate by medium-dose UVA1 phototherapy. Eur J Med Res 2002;7: 315322.
  • 113
    Simon HU. The neutralization of Interleukin-5 as a therapeutic concept in allergic inflammation. Sarcoidosis Vasc Diffuse Lung Dis 2002;19: 2528.
  • 114
    Hamelmann E, Oshiba A, Loader J, Larsen GL, Gleich G, Lee J et al. Anti-interleukin-5 antibody prevents airway hyperresponsiveness in a murine model of airway sensitisation. Am J Respir Crit Care Med 1997;155: 819825.
  • 115
    Leckie MJ, Ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM et al. Effects of an interleukin-5 blocking antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet 2000;356: 21442148.
  • 116
    Ploetz SG, Simon HU, Darsow U, Simon D, Vassina E, Yousefi S et al. Use of anti-interleukin-5 antibody in hypereosinophilic syndrome with eosinophilic dermatitis. N Eng J Med 2003;349: 23322337.